Situation: The nurse works in the obstetric admitting and labor unit of a provincial hospital that receives referrals from birthing facilities of rural health units (RHUs). A 27-year-old client with a stable, unruptured tubal ectopic pregnancy receives a single intramuscular dose of methotrexate (day 1). Her serum human chorionic gonadotropin (hCG) level is to be followed. Which change in the hormone level indicates an adequate response to the drug?

After single-dose methotrexate, the hormone level is measured on day 4 and day 7; a fall of at least 15% between these two values indicates response, and weekly tests then continue until the level is undetectable. The level often rises during the first days after the injection, so day 1 is not used as the baseline. A slow rise over 48 hours describes a failing or ectopic pregnancy before treatment, not a response.

Clinical context

A stable, unruptured tubal ectopic pregnancy treated with single-dose methotrexate requires serial serum hCG monitoring to confirm trophoblastic tissue is resolving. The timing and interpretation of these values are specific and frequently tested on licensure exams because they guide the decision to repeat the dose or proceed to surgery.

The standard single-dose protocol designates the day of methotrexate injection as day 1, then measures hCG on day 4 and day 7; an adequate response is defined as a fall of at least 15% from the day 4 value to the day 7 value. ^[1][2] This threshold is not arbitrary — it reflects the expected decline in trophoblastic hCG production once methotrexate has interrupted folate-dependent DNA synthesis in actively dividing trophoblast cells.

Watch out! The day 1 hCG level is not used as the baseline for judging response. Methotrexate does not immediately halt hCG secretion, and the hormone level frequently rises during the first 72 to 96 hours after injection as already-synthesized hCG is released and as trophoblast cells undergo initial swelling and lysis. ^[1][3] Therefore, comparing day 4 to day 1 would misclassify many responding patients as treatment failures.

In the single-dose protocol, the day 4 value serves as the reference point, and the day 7 value is compared against it. A decline of ≥15% from day 4 to day 7 indicates that the trophoblastic tissue is involuting and that no additional methotrexate or surgical intervention is immediately required. ^[2][3] Weekly hCG measurements then continue until the level becomes undetectable, confirming complete resolution.

If the day 4 to day 7 decline is less than 15%, the patient is considered to have a suboptimal response. Current evidence suggests that in selected clinically stable patients, observation may be extended to day 10 before declaring treatment failure, because some patients show a delayed but ultimately adequate decline. ^[2] However, the initial decision point remains the day 4-to-day 7 comparison.

Key point! A slow rise in hCG over 48 hours describes the natural history of a failing or ectopic pregnancy before any treatment is given — it is a diagnostic clue, not a marker of methotrexate response. Once methotrexate has been administered, the expected pattern shifts to a decline between days 4 and 7.

Option	Interpretation	Why it is incorrect or correct
1. Fall of at least 50% from day 1 to day 4	Uses day 1 as baseline and demands an unrealistic early drop	hCG often rises initially after methotrexate; day 1 is not the reference point [1][3]
2. Fall of at least 15% from day 4 to day 7	Standard definition of adequate response	Correct — matches the single-dose protocol and has a positive predictive value of 93% for success [3]
3. Fall of at least 15% from day 1 to day 4	Compares against the wrong baseline	Day 1 hCG may still be rising; this comparison is not used clinically [1]
4. Rise of no more than 35% over any 48 hours	Describes pre-treatment ectopic pregnancy behavior	Not a criterion for methotrexate response; reflects untreated trophoblast activity

The day 4-to-day 7 comparison is also clinically practical because it allows time for methotrexate to exert its full effect on trophoblast proliferation. Methotrexate inhibits dihydrofolate reductase, depleting the reduced folate pool needed for purine and pyrimidine synthesis; cells that were in S-phase at the time of exposure die over the following days, and hCG production falls accordingly. The 15% threshold balances sensitivity for detecting true failure against the risk of unnecessary repeat dosing or surgery. ^[2]

For the nurse admitting this client, the priority is to ensure that serum hCG is drawn on the correct days, that the day 4 value is clearly identified as the baseline for the day 7 comparison, and that any signs of tubal rupture — increasing abdominal pain, peritoneal irritation, orthostatic changes, or falling hemoglobin — are reported immediately regardless of the hCG trend.

```